Ilyang Pharm (007570) - Total Liabilities

Latest as of June 2025: ₩205.41 Billion KRW ≈ $139.20 Million USD

Based on the latest financial reports, Ilyang Pharm (007570) has total liabilities worth ₩205.41 Billion KRW (≈ $139.20 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Ilyang Pharm - Total Liabilities Trend (2002–2024)

This chart illustrates how Ilyang Pharm's total liabilities have evolved over time, based on quarterly financial data. See Ilyang Pharm (007570) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Ilyang Pharm Competitors by Total Liabilities

The table below lists competitors of Ilyang Pharm ranked by their total liabilities.

Company	Country	Total Liabilities
Chaman Lal Setia Exports Limited NSE:CLSEL	India	Rs2.12 Billion
Megaforce Co Ltd TWO:3294	Taiwan	NT$2.57 Billion
Silicon Optronics Inc TW:3530	Taiwan	NT$215.53 Million
Oando PLC JSE:OAO	South Africa	ZAC7.26 Trillion
Reit Azorim HF Living Ltd TA:AZRT	Israel	ILA2.19 Billion
SCI Pharmtech Inc TW:4119	Taiwan	NT$1.54 Billion
Acme United Corporation NYSE MKT:ACU	USA	$78.52 Million
INFOM KLSE:0265	Malaysia	RM244.87 Million

Liability Composition Analysis (2002–2024)

This chart breaks down Ilyang Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ilyang Pharm (007570) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.87	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.46	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ilyang Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ilyang Pharm (2002–2024)

The table below shows the annual total liabilities of Ilyang Pharm from 2002 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩189.63 Billion ≈ $128.51 Million	+18.33%
2023-12-31	₩160.25 Billion ≈ $108.60 Million	-22.33%
2022-12-31	₩206.33 Billion ≈ $139.83 Million	-7.27%
2021-12-31	₩222.51 Billion ≈ $150.79 Million	+14.58%
2020-12-31	₩194.19 Billion ≈ $131.60 Million	-9.56%
2019-12-31	₩214.72 Billion ≈ $145.51 Million	-3.44%
2018-12-31	₩222.37 Billion ≈ $150.70 Million	-1.34%
2017-12-31	₩225.39 Billion ≈ $152.74 Million	+5.37%
2016-12-31	₩213.91 Billion ≈ $144.96 Million	-3.04%
2015-12-31	₩220.62 Billion ≈ $149.51 Million	-10.81%
2014-12-31	₩247.37 Billion ≈ $167.64 Million	+15.32%
2013-12-31	₩214.50 Billion ≈ $145.37 Million	+33.50%
2009-12-31	₩160.67 Billion ≈ $108.89 Million	+39.31%
2004-12-31	₩115.33 Billion ≈ $78.16 Million	+26.51%
2003-12-31	₩91.16 Billion ≈ $61.78 Million	-7.51%
2002-12-31	₩98.56 Billion ≈ $66.80 Million	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$158.52 Million

₩233.92 Billion KRW

Market Cap Rank

#17539 Global

#738 in Korea

Share Price

₩13050.00

Change (1 day)

+0.00%

52-Week Range

₩12300.00 - ₩15130.00

All Time High

₩95982.23